Description
Deep Genomics is at the forefront of integrating artificial intelligence with biology to revolutionize the discovery and design of genetic medicines. Utilizing their proprietary BioFM (Biological Foundation Model) platform, Deep Genomics aims to accelerate the drug discovery process by identifying molecular targets that might be overlooked by traditional methods. The platform is designed to generate differentiated predictions relevant to molecular design and target biology discovery, ensuring reliability and reproducibility at scale.
The BioFM platform incorporates lab-in-the-loop workflows, which involve designing and generating datasets for training models from scratch or fine-tuning them for specific applications. This approach allows for rapid advancement in drug discovery, both internally and in collaboration with major pharmaceutical partners. The platform's capabilities are underpinned by robust information and software systems that ensure scalable, workflow-integrated AI.
Deep Genomics' models, such as BigRNA and REPRESS, are instrumental in predicting the effects of genetic variants and understanding RNA biology. BigRNA, for instance, is trained on over a trillion signals from high-throughput sequencing datasets, allowing it to predict on- and off-target effects of genetic medicines. REPRESS, on the other hand, excels in predicting cell-type-specific microRNA binding and mRNA degradation, outperforming other methods in various tasks.
The company operates experimental facilities in Toronto and Cambridge, Massachusetts, where scientists work closely with machine learning experts to design experiments that accelerate their mission. Deep Genomics is led by a team of seasoned experts in genomics, drug development, and AI, including CEO Brian O'Callaghan and Founder Brendan Frey.
Deep Genomics is headquartered in Toronto, with additional offices in Boston. Their strategic location in the MaRS Discovery District places them at the heart of a thriving tech hub, surrounded by leading research institutions and AI labs.
Deep Genomics's Core Features
AI-driven genetic medicine discovery
BioFM platform for molecular design
Lab-in-the-loop workflows
BigRNA model for RNA biology
REPRESS model for miRNA binding
Experimental facilities in Toronto and Cambridge
Collaboration with major pharma partners
Robust software systems for AI integration
How to use Deep Genomics?
Configure: Set up BioFM platform for specific applications
Use: Leverage models like BigRNA and REPRESS for predictions
Optimise: Fine-tune models with new datasets
Validate: Use lab-in-the-loop workflows for experimental validation
Deep Genomics's Use Cases
- Genetic Medicine Discovery
- Molecular Design
- RNA Biology Research
- miRNA Binding Prediction
- Drug Discovery Collaboration